researcher in futuristic laboratory using artificial intelligence for drug discovery
Media Coverage

AI-Driven Solutions Poised for Big Impact on Drug Discovery

Biocompare

Biocompare recently asked three experts what they thought about the use of artificial intelligence and machine learning in drug discovery, a topic that has been front and center lately, discussed regularly at scientific meetings as well as in mainstream publications. In the Q&A, Grant Wishart, Ph.D., Director CADD & Structural Biology at Charles River Laboratories; Stephan Steigele, Ph.D., Head of Science Genedata; and Matt Segall, Ph.D., CEO at Optibrium, share their considerable insights and thoughts on the future.

Read Full Q&A Session